Literature DB >> 22098097

Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort.

Maria Benito de Valle1, Einar Björnsson, Björn Lindkvist.   

Abstract

BACKGROUND: Population-based studies on the epidemiology of primary sclerosing cholangitis (PSC) are sparse. AIMS: To investigate mortality and risk of cancer, and to identify risk factors for hepatobiliary cancer and the combined end-point liver related death or liver transplantation (OLT) in a population-based PSC cohort in Västra Götaland, Sweden.
METHODS: Primary sclerosing cholangitis cases were identified in diagnostic registries. Case validation and follow up was provided through individual review of case files and linkage to the Swedish Cancer and Cause of Death registries. Standardized mortality ratio (SMR) and standardized incidence ratio (SIR) for cancer were calculated in relation to the background population. Cox's proportional hazards analysis was used to calculate crude and adjusted relative risks (RRs).
RESULTS: A total of 199 PSC patients were identified between 1992 and 2005. SMR in the PSC cohort was 4.20 (95% confidence interval (CI), 3.01-5.69). SIR for hepatobiliary cancer, cholangiocarcinoma and colorectal cancer were 177 (110-271), 868 (505-1390) and 2.87 (0.33-10.4) respectively. Age (RR=1.25 (1.01-1.53) per decade), female gender (RR=2.01 (1.09-3.72)), cholangitis (RR=2.56 (1.20-5.64)) and bilirubin (RR=3.95 (1.96-10.75) highest vs lowest quartile) were associated with the risk of liver related death or OLT. Age was associated with the risk of hepatobiliary cancer (RR 1.40 (1.01-1.95) per decade).
CONCLUSIONS: Primary sclerosing cholangitis was associated with a four-fold increase in mortality in this population-based study. In accordance with previous studies, the risk of hepatobiliary cancer was dramatically increased. However, the increased risk of colorectal cancer reported in previous studies could not be confirmed.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 22098097     DOI: 10.1111/j.1478-3231.2011.02614.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  23 in total

Review 1.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 2.  The evolution of natural history of primary sclerosing cholangitis.

Authors:  Will R Takakura; James H Tabibian; Christopher L Bowlus
Journal:  Curr Opin Gastroenterol       Date:  2017-03       Impact factor: 3.287

Review 3.  Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.

Authors:  Rosy Wang; Rupert W Leong
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 4.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 5.  Preneoplastic conditions underlying bile duct cancer.

Authors:  Lena Sibulesky; Justin Nguyen; Tushar Patel
Journal:  Langenbecks Arch Surg       Date:  2012-03-06       Impact factor: 3.445

6.  Variations in primary sclerosing cholangitis across the age spectrum.

Authors:  John E Eaton; Bryan M McCauley; Elizabeth J Atkinson; Brian D Juran; Erik M Schlicht; Mariza de Andrade; Konstantinos N Lazaridis
Journal:  J Gastroenterol Hepatol       Date:  2017-10       Impact factor: 4.029

7.  ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; M Edwyn Harrison
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

Review 8.  Genetics of primary sclerosing cholangitis and pathophysiological implications.

Authors:  Xiaojun Jiang; Tom H Karlsen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-15       Impact factor: 46.802

9.  Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Vivian S Gainer; Su-Chun Cheng; Tianxi Cai; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  J Crohns Colitis       Date:  2014-02-19       Impact factor: 9.071

10.  Intrahepatic cholangiocarcinoma in a low endemic area: rising incidence and improved survival.

Authors:  Caroline D M Witjes; Henrike E Karim-Kos; Otto Visser; Esther de Vries; Jan N M IJzermans; Robert A de Man; Jan Willem W Coebergh; Cornelis Verhoef
Journal:  HPB (Oxford)       Date:  2012-08-17       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.